JCO Oncology Practice,
Journal Year:
2024,
Volume and Issue:
20(11), P. 1481 - 1490
Published: Nov. 1, 2024
Over
the
next
few
years,
analysis
of
circulating
tumor
DNA
(ctDNA)
through
liquid
biopsy
is
expected
to
enter
clinical
practice
and
revolutionize
approach
biomarker
testing
treatment
selection
in
GI
cancers.
In
fact,
growing
evidence
support
use
ctDNA
as
a
noninvasive,
effective,
highly
specific
tool
for
molecular
profiling
Analysis
blood
has
been
investigated
multiple
settings
including
early
detection,
minimal
residual
disease
evaluation,
diagnosis
evaluation
prognostic/predictive
biomarkers
targeted
selection,
longitudinal
monitoring
response,
identification
resistance
mechanisms.
Here,
we
review
applications,
advantages,
limitations
precision
oncology
Nano Convergence,
Journal Year:
2024,
Volume and Issue:
11(1)
Published: May 29, 2024
Abstract
Liquid
biopsy
has
emerged
as
a
promising
non-invasive
strategy
for
cancer
diagnosis,
enabling
the
detection
of
various
circulating
biomarkers,
including
tumor
cells
(CTCs),
nucleic
acids
(ctNAs),
tumor-derived
small
extracellular
vesicles
(sEVs),
and
proteins.
Surface-enhanced
Raman
scattering
(SERS)
biosensors
have
revolutionized
liquid
by
offering
sensitive
specific
methodologies
these
biomarkers.
This
review
comprehensively
examines
application
SERS-based
identification
analysis
biomarkers
CTCs,
ctNAs,
sEVs
proteins
in
diagnosis.
The
discussion
encompasses
diverse
range
SERS
biosensor
platforms,
label-free
assay,
magnetic
bead-based
microfluidic
device-based
system,
paper-based
each
demonstrating
unique
capabilities
enhancing
sensitivity
specificity
critically
assesses
strengths,
limitations,
future
directions
Trends in cancer,
Journal Year:
2024,
Volume and Issue:
10(7), P. 643 - 654
Published: June 4, 2024
Systemic
treatment
of
resectable
non-small
cell
lung
cancer
(NSCLC)
is
evolving
with
emerging
neoadjuvant,
perioperative,
and
adjuvant
immunotherapy
approaches.
Circulating
tumor
DNA
(ctDNA)
detection
at
clinical
diagnosis,
during
neoadjuvant
therapy,
or
after
resection
may
discern
high-risk
patients
who
might
benefit
from
therapy
escalation
switch.
This
Review
summarizes
translational
implications
data
supporting
ctDNA-based
risk
determination
in
NSCLC
outstanding
questions
regarding
ctDNA
validity/utility
as
a
prognostic
biomarker.
We
discuss
capabilities
to
refine
tumor-node-metastasis
(TNM)
staging
adenocarcinoma,
dynamics
for
identifying
deriving
suboptimal
benefit,
postoperative
molecular
residual
disease
(MRD)
escalate
systemic
therapy.
Considering
differential
relapse
characteristics
landmark
MRD-negative/MRD-positive
patients,
we
propose
how
integrate
pathological
response
optimal
stratification.
American Society of Clinical Oncology Educational Book,
Journal Year:
2025,
Volume and Issue:
45(2)
Published: Jan. 1, 2025
The
growing
sophistication
of
tumor
molecular
profiling
has
helped
to
slowly
transition
oncologic
care
toward
a
more
personalized
approach
in
different
types,
including
bladder
cancer.
National
Comprehensive
Cancer
Network
recommends
that
all
patients
with
stage
IVA
and
IVB
urothelial
carcinoma
have
analysis
integrates
at
least
FGFR3
testing
help
facilitate
the
selection
future
therapeutic
options.
Sequencing
tumor-derived
tissue
is
mainstay
obtain
this
genomic
testing,
but
as
other
cancers,
there
been
extensive
research
into
integration
liquid
biopsies
longitudinal
management.
Liquid
broadly
refer
isolation
both
cellular
noncellular
components
proteins
nucleic
acids
such
mRNA
circulating
free
DNA
within
sample.
Although
protein-based
cells
are
options,
bulk
promising
cancer
investigating
role
plasma-based
(ctDNA).
Currently,
universal
consensus
on
optimal
preanalytic
analytic
approaches
not
fully
defined,
exact
should
screening,
diagnosis,
prognostication,
treatment
selection,
monitoring
yet
known.
Still,
it
can
be
expected
ctDNA
will
part
appropriate
management
muscle-invasive
metastatic
near
future.
In
review,
goal
provide
practical
overview
current
ongoing
trials.
Nature Medicine,
Journal Year:
2024,
Volume and Issue:
30(9), P. 2508 - 2516
Published: June 1, 2024
Abstract
Circulating
tumor
DNA
(ctDNA)
is
emerging
as
a
potential
biomarker
in
early-stage
urothelial
cancer,
but
its
utility
metastatic
disease
remains
unknown.
In
the
phase
3
KEYNOTE-361
study,
pembrolizumab
with
and
without
chemotherapy
was
compared
alone
patients
cancer.
The
study
did
not
meet
prespecified
efficacy
thresholds
for
statistical
significance.
To
identify
biomarkers
of
response,
we
retrospectively
evaluated
association
pre-
posttreatment
ctDNA
clinical
outcomes
subset
who
received
(
n
=
130)
or
KEYNOTE-361.
Baseline
associated
best
overall
response
(BOR;
P
0.009),
progression-free
survival
<
0.001)
(OS;
(all;
>
0.05).
Chemotherapy
induced
larger
decreases
from
baseline
to
treatment
cycle
2
than
pembrolizumab;
however,
change
87)
more
BOR
4.39
×
10
−5
)
OS
7.07
102;
BOR:
1.01
−4
;
OS:
0.018).
Tumor
tissue-informed
versions
metrics
were
most
show
statistically
significant
independent
value
explaining
beyond
radiographic
by
RECIST
v.1.1
when
jointly
modeled
(pembrolizumab
0.364;
0.823).
These
results
suggest
distinct
patterns
early
changes
immunotherapy
differences
their
long-term
outcomes,
which
provide
preliminary
insights
into
liquid
biopsies
monitoring
Clinical
trial
registration:
NCT02853305
.
Clinical Chemistry and Laboratory Medicine (CCLM),
Journal Year:
2024,
Volume and Issue:
62(11), P. 2111 - 2127
Published: March 5, 2024
Cancer
continues
to
pose
significant
challenges
the
medical
community.
Early
detection,
accurate
molecular
profiling,
and
adequate
assessment
of
treatment
response
are
critical
factors
in
improving
quality
life
survival
cancer
patients.
Accumulating
evidence
shows
that
circulating
tumor
DNA
(ctDNA)
shed
by
tumors
into
peripheral
blood
preserves
genetic
epigenetic
information
primary
tumors.
Notably,
methylation,
an
essential
stable
modification,
exhibits
both
cancer-
tissue-specific
patterns.
As
a
result,
ctDNA
methylation
has
emerged
as
promising
marker
for
noninvasive
testing
clinics.
In
this
review,
we
summarize
existing
techniques
describe
current
research
status
present
potential
applications
ctDNA-based
assays
clinic.
The
insights
presented
article
could
serve
roadmap
future
clinical
methylation.
Virchows Archiv,
Journal Year:
2023,
Volume and Issue:
484(2), P. 169 - 179
Published: Nov. 20, 2023
Abstract
Medical
oncology
is
rapidly
evolving
with
the
implementation
of
personalized,
targeted
therapies.
Advances
in
molecular
diagnostics
and
biologic
understanding
cancer
pathophysiology
led
to
identification
specific
genetic
alterations
as
drivers
progression.
Further,
improvements
drug
development
enable
direct
interference
these
pathways,
which
allow
tailoring
personalized
treatments
based
on
a
distinct
characterization
tumors.
Thereby,
we
are
currently
experiencing
paradigm-shift
treatment
cancers
towards
cancer-type
agnostic,
molecularly
targeted,
However,
this
concept
has
several
important
hurdles
limitations
overcome
ultimately
increase
proportion
patients
benefitting
from
precision
approach.
These
include
assessment
clinical
relevancy
identified
alterations,
capturing
interpreting
levels
heterogeneity
intra-tumoral
or
time-dependent
evolution,
challenges
practical
routine
care.
In
present
review,
summarize
current
state
cancer-agnostic
oncology,
discuss
tumor
boards,
consider
therapy.
provide
an
outlook
potential
future
developments
including
functionality
assessments
broader
use
liquid
biopsies
order
obtain
more
comprehensive
longitudinal
information
that
might
guide
therapy
future.
Cancer Management and Research,
Journal Year:
2024,
Volume and Issue:
Volume 16, P. 1031 - 1042
Published: Aug. 1, 2024
Human
life
expectancy
is
significantly
impacted
by
cancer,
with
liquid
biopsy
emerging
as
an
advantageous
method
for
cancer
detection
because
of
its
noninvasive
nature,
high
accuracy,
ease
sampling,
and
cost-effectiveness
compared
conventional
tissue
techniques.
Liquid
shows
promise
in
early
detection,
real-time
monitoring,
personalized
treatment
various
cancers,
including
lung,
cervical,
prostate
offers
innovative
approaches
diagnosis
management.
By
utilizing
circulating
tumor
DNA,
cells,
exosomes
biomarkers,
enables
the
tracking
progression.
Various
techniques
commonly
used
sciences
research,
such
polymerase
chain
reaction
(PCR),
next-generation
sequencing
(NGS),
droplet
digital
PCR,
are
employed
to
assess
progression
on
basis
different
indicators.
This
review
examines
latest
advancements
markers-circulating
DNA
(ctDNA),
cells
(CTCs),
exosomes-for
over
past
three
years,
a
focus
their
methodologies
clinical
applications.
It
encapsulates
pivotal
aims
biopsy,
therapy
response
prediction,
prognostication,
relevance
minimal
residual
disease,
while
also
addressing
challenges
facing
routine
adoption.
combining
research
practical
experiences,
this
work
focuses
discussing
significance
methylation
biomarkers
applications
screening,
auxiliary
diagnosis,
companion
recurrence
monitoring.
These
discussions
may
help
enhance
application
throughout
entire
process
treatment,
thereby
providing
patients
more
precise
effective
plans.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(16), P. 2882 - 2882
Published: Aug. 19, 2024
Lung
cancer,
including
both
non-small
cell
lung
cancer
and
small
remains
the
leading
cause
of
cancer-related
mortality
worldwide,
representing
18%
total
deaths
in
2020.
Many
patients
are
identified
already
at
an
advanced
stage
with
metastatic
disease
have
a
worsening
prognosis.
Recent
advances
genetic
understanding
opened
new
avenues
for
personalized
treatments
targeted
therapies.
This
review
examines
latest
discoveries
genetics
discusses
key
biomarkers,
analyzes
current
clinical
therapies
based
on
this
information.
It
will
conclude
discussion
future
prospects
potential
research
directions.
Expert Review of Molecular Diagnostics,
Journal Year:
2024,
Volume and Issue:
24(4), P. 311 - 331
Published: April 2, 2024
Introduction
Oral
Squamous
Cell
Carcinoma
(OSCC),
the
sixth
most
widespread
malignancy
in
world,
accounts
for
90%
of
all
cases
oral
cancer.
The
primary
risk
factors
are
tobacco
chewing,
alcohol
consumption,
viral
infection,
and
genetic
modifications.
OSCC
has
a
high
morbidity
rate
due
to
lack
early
diagnostic
methods.
Nowadays,
liquid
biopsy
plays
vital
role
initial
diagnosis
ctNAs
extracted
from
saliva
serum/plasma
offer
meaningful
insights
into
tumor
genetics
dynamics.
interplay
these
elements
showcases
their
significance
advancing
noninvasive,
effective
detection
monitoring.
